EGFRvIII

EGFRvIII Overview

English NameEpidermal growth factor receptor variant IIIApproved Drugs0
Drugs in Clinical Trials14Target Synonym
Highest Development StagePhase 2 Clinical
English NameEpidermal growth factor receptor variant III
Target Synonym
Approved Drugs0
Drugs in Clinical Trials14
Highest Development StagePhase 2 Clinical

EGFRvIII Background

The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is the cell-surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands. The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Mutations affecting EGFR expression or activity could result in cancer. The type III EGF deletion mutant receptor (EGFRvIII) is the most common mutation and was first identified in primary human glioblastoma tumors. This tumor-specific antigen is ligand-independent, contains a constitutively active tyrosine kinase domain, and has been shown to be present in a number of human malignancies. EGFRvIII has been selected as a target for CAR-modified T-cell studies in recent years.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
WSD-0922WSD0922; WSD-0922Phase 2 ClinicalWayshine Biopharm International LtdAstrocytoma; Carcinoma, Non-Small-Cell Lung; Glioblastoma
Details
Anti-EGFRvIII-CAREGFRvIII CAR; Anti-EGFRvIII-CARPhase 2 ClinicalKite Pharma, National Cancer InstituteBrain Neoplasms; Glioblastoma; Glioma; Gliosarcoma
Details
Recombinant anti-EGFR chimeric monoclonal antibody (Shanghai CP Guojian)CPGJ-602; 602; CPGJ602; CPGJ 602Phase 2 ClinicalSunshine GuoJian Pharmaceutical (Shanghai) Co LtdColorectal Neoplasms
Details
WSD-0922-FUWSD0922-FU; WSD-0922-FUPhase 2 ClinicalWayshine Biopharm International LtdAstrocytoma; Carcinoma, Non-Small-Cell Lung; Glioblastoma; Lung Neoplasms; Neoplasms; Solid tumours
Details
EGFRvIII-directed CAR-T cell tharapy (Novartis/University of Pennsylvania)LXF-821Phase 1 ClinicalNovartis Pharma Ag, University Of PennsylvaniaGlioblastoma
Details
EGFRvIII-CARPhase 1 ClinicalDuke University Medical CenterGlioblastoma
Details
Metabolically Armed EGFRvIII CAR-T cells therapy (Leman Biotech)Meta10-EGFRvIII; LMC005Phase 1 ClinicalLeman Biotech Co LtdGlioblastoma
Details
APTN-101CBRX-101; APTN 101Phase 1 ClinicalAdaptin Bio IncGlioblastoma; Glioma
Details
Autologous Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13R alpha2 CAR (E-SYNC) T Cells therapy(California Institute For Regenerative Medicine)Phase 1 ClinicalCalifornia Institute For Regenerative Medicine, National Cancer InstituteGlioblastoma
Details
Targeted EGFRvIII autochimeric antigen receptor T cell therapy (DCTY)DCTY0801; DCTY-0801Phase 1 ClinicalBeijing DCTY Biotech Co LtdGlioblastoma; Glioma
Details
SNC-109SNC109; SNC-109Phase 1 ClinicalShanghai Simnova Biotechnology Co LtdGlioblastoma
Details
RO-7428731RO-7428731; RG-6156Phase 1 ClinicalF. Hoffmann-La Roche LtdGlioblastoma
Details
GNC-039GNC-039Phase 1 ClinicalSichuan Baili Pharmaceutical Co LtdGlioma; Hematologic Neoplasms; Neoplasm Metastasis; Solid tumours
Details
89Zr-ABT806ClinicalHuashan HospitalGlioma
Details
  • Overview
  • Product List
  • Clinical Drug Information
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland